CClinicalTrials.gg
WithdrawnNCT05713383Updated Jan 16, 2026

The Role of Perturbed Auditory Information for Self-motion in Gait

An interventional study of Auditory Feedback in Gait, sponsored by University of Nebraska. Withdrawn at 1 site in United States. Open to participants aged 19 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by University of Nebraska · Not applicable, Interventional, and Basic science

Why this study was withdrawn
Pilot indicated that this part of the project, which is the last part, would not be feasible in the expected time frame.
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
19 Years to 35 Years
Sex
All
01

Study summary

As people walk and interact with objects such as when opening a door, their movements make sounds. It is possible that these sounds are also used as feedback to stabilize and adapt movement. There is some evidence for such a connection between the auditory and motor systems in activities of daily living, yet the empirical work is insufficient because the role of the auditory system in movement is a relatively neglected topic. The objective of this study is to address this gap. The study will also evaluate the potential for improvements in movement stability and variability by restricting or augmenting the auditory feedback from the participants' footstep sounds.

Read the detailed description

As people walk and interact with objects such as when opening a door, their movements make sounds. It is possible that these sounds are also used as feedback to stabilize and adapt movement. There is some evidence for such a connection between the auditory and motor systems in activities of daily living, yet the empirical work is insufficient because the role of the auditory system in movement is a relatively neglected topic. The objective of this study is to address this gap. The study will also evaluate the potential for improvements in movement stability and variability by restricting or augmenting the auditory feedback from the participants' footstep sounds. Eligibility is based on inclusion and exclusion criteria determined via a self-report questionnaire. The inclusion criteria are age and overall health status (young healthy adults, 19-35) and self-reported ability to walk comfortably for half an hour. Exclusion criteria include known hearing impairment, history of back or lower extremity injury, surgery that affects mobility, neurological disease or impairment that limits the ability to walk (Cerebral palsy). The study will randomly split the participants in a control and experimental group. Participants will perform trials in one condition only, quiet walking or control. Participants will visit the lab five times in the span of two weeks. The first and last sessions will serve for pre-post comparisons.

02

Conditions studied

  • Gait
03

In context

Lead sponsor

University of Nebraska is the lead sponsor of 473 studies on the registry; 66 are open to participants now.

Of its 75 completed or terminated interventional studies of FDA-regulated products, 46 (61%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • self-reported tolerance to 30 minute exercise
  • self-reported ability to walk comfortably for half an hour

Exclusion criteria

Exclusion Criteria:

  • known hearing or visual impairment
  • currently being pregnant
  • history of back or lower extremity injury, surgery that affects mobility, and neurological disease or impairment that limit the ability to walk
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • No intervention
    Walking

    Walking normally without restriction

  • Experimental
    Walking Quietly

    Participants instructed to make little noise while walking.

    Behavioral: Auditory Feedback

Interventions

  • BehavioralAuditory Feedback

    Sound amplification is used to accentuate participants' footsteps, while asking them to step softly so as to reduce this sound.

06

What researchers measure

Primary outcomes

  1. Gait instability measured with the maximum Lyapunov exponent (MLE)

    The MLE is sensitive to the degree to which the gait cycle tends to diverge from its average repeated pattern. It is typically computed with the Rosenstein algorithm applied to motion-tracking data recorded while the participant is walking. More specifically, the marker is placed on the participant's upper body close to the center-of-mass. MLE equal to zero indicates a neutrally stable dynamic with perfectly repeatable oscillation. Paradoxically, this is maladaptive. Very low values of MLE close to zero tend to be associated with motor disorders. Increasingly positive values of MLE correspond to higher tolerance for dynamic instability and are associated with a healthy gait pattern. There are also exceptions, not relevant to the present study, where very high instability corresponds to specific motor disorders.

    Time frame: The time frame to measure changes in the outcome variable is two weeks, from the first to last measurement. The time frame to obtain one sample is a few minutes of walking.

07

Study locations

1 site
  • University of Nebraska-Omaha, Department of Biomechanics,
    Omaha, Nebraska 68182, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05713383
Lead sponsor
University of Nebraska
Responsible party
Sponsor
First posted
Feb 6, 2023
Start date
Mar 1, 2026 (estimated)
Primary completion
Apr 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Jan 16, 2026

Study contacts

Dobromir Dotov, PhD
principal investigator · University of Nebraska

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion